FDA Approves First Cell-Based Gene Therapy for Beta-Thalassemia
MONDAY, Aug. 22, 2022 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
Zynteglo is a one-time, single-dose gene therapy product. Each dose of Zynteglo is customized and created using the patient's own bone marrow stem cells, which are genetically modified to produce functional beta-globin. The application was granted a rare pediatric disease voucher, as well as priority review, fast-track, breakthrough therapy, and orphan designations.
The approval was based on two multicenter clinical studies. Of 41 patients receiving Zynteglo, 89 percent achieved transfusion independence, defined as maintaining a predetermined level of hemoglobin without needing any red blood cell transfusions for at least 12 months. The most common adverse reactions seen with Zynteglo included reduced platelet and other blood cell levels, mucositis, febrile neutropenia, vomiting, fever, alopecia, nosebleed, abdominal pain, musculoskeletal pain, cough, headache, diarrhea, rash, constipation, nausea, decreased appetite, pigmentation disorder, and itch.
Given the potential risk for blood cancer associated with this treatment, patients receiving Zynteglo should have their blood monitored for at least 15 years for evidence of cancer. The FDA says patients should also be monitored for hypersensitivity reactions during Zynteglo administration and for thrombocytopenia and bleeding.
Approval of Zynteglo was granted to bluebird bio.
Related Posts
Water Weight: How to Lose It for Good
FRIDAY, Jan. 13, 2023 (HealthDay News) -- Water weight. It's the bane of dieters...
Cuando el acceso a la atención médica es igual, la brecha racial en la supervivencia del cáncer de próstata desaparece
VIERNES, 13 de octubre de 2023 (HealthDay News) -- A los hombres de todas las...
Telehealth Boosts Odds That Patients Show Up for Post-Surgery Care
MONDAY, Oct. 17, 2022 (HealthDay News) -- Telehealth became a common way for...